Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer
-
Published:2022-12-09
Issue:3
Volume:197
Page:593-602
-
ISSN:0167-6806
-
Container-title:Breast Cancer Research and Treatment
-
language:en
-
Short-container-title:Breast Cancer Res Treat
Author:
Shimomura AkihikoORCID, Yoshida Masayuki, Kubo Takashi, Yamashita Satoshi, Noguchi Emi, Nagayama Aiko, Hanamura Toru, Okazaki Miki, Mukohara Toru, Tsuruga Asako, Tanaka Kiyo, Kawamura Yukino, Higuchi Toru, Takahashi Yoko, Kurozumi Sasagu, Hayashida Tetsu, Ichikawa Hitoshi, Ushijima Toshikazu, Suto Akihiko
Abstract
Abstract
Purpose
Male breast cancer (MBC) is a rare cancer accounting for only 1% of all male cancers and is, therefore, poorly studied. We aimed to characterize the subtypes of MBC in Japanese patients based on genetic profiling, the presence of tumor-infiltrating cells, and the expression of immunohistochemical markers.
Methods
This retrospective study included 103 patients with MBC diagnosed between January 2009 and December 2019 at various hospitals in Japan. Clinicopathological patient characteristics were obtained from medical records, and formalin-fixed paraffin-embedded tissue specimens were analyzed for histological markers, mutations of 126 genes, BRCA1 methylation, and stromal tumor-infiltrating lymphocytes.
Results
The median patient age was 71 (range 31–92) years. T1-stage tumors were the most frequent (47.6%), and most were node negative (77.7%). The majority of tumors were positive for estrogen receptor (98.1%), progesterone receptor (95.1%), and androgen receptor (96.1%), and BRCA2 was the most frequently mutated gene (12.6%). The most common treatment was surgery (99.0%), either total mastectomy (91.1%) or partial mastectomy (7.0%). Survival analysis showed a 5-year recurrence-free survival rate of 64.4% (95% confidence interval [CI] 46.7–88.8) and a 5-year overall survival rate of 54.3% (95% CI 24.1–100.0).
Conclusion
Japanese MBC is characterized by a high rate of hormonal receptor positivity and BRCA2 somatic mutation. Due to the observed clinicopathological differences in MBC between the Western countries and Japan, further prospective studies are needed to evaluate the most suitable treatment strategies.
Funder
Chugai Pharmaceutical Co. Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference33 articles.
1. Arslan UY, Oksüzoğlu B, Ozdemir N, Aksoy S, Alkış N, Gök A, Kaplan MA, Gümüş M, Berk V, Uncu D, Baykara M, Colak D, Uyetürk U, Türker I, Işıkdoğan A (2012) Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol 29:554–560. https://doi.org/10.1007/s12032-011-9978-9 2. Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137:678–687. https://doi.org/10.7326/0003-4819-137-8-200210150-00013 3. Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434–1443. https://doi.org/10.1093/annonc/mdt025 4. Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239. https://doi.org/10.1200/JCO.2009.23.8162 5. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173:37–48. https://doi.org/10.1007/s10549-018-4921-9
|
|